Can Fezonatant Improve Menopausal Mood Swings? Research progress

Fezolinetant, as a neurokinin 3 (NK3) receptor antagonist, is a new non-hormonal drug that has attracted much attention in the field of treating menopausal vasomotor symptoms in recent years. Its main approved indication is moderate to severe hot flashes and night sweats, which are often caused by oversensitivity of the hypothalamic heat regulatory center to changes in estrogen. However, with the deepening of clinical application and the continuous advancement of research on the mechanisms of menopausal syndrome symptoms, people have begun to pay attention to whether fezonatant can provide additional relief in aspects such as mood swings, anxiety and depression. Menopausal women often experience psychological distress such as emotional instability, irritability, insomnia, and even depression. These problems are often related to endocrine changes, sleep disorders, and life events, which seriously affect the quality of life.

Current published studies generally focus on the direct effect of fezonem on physical symptoms such as hot flashes. However, in the secondary or exploratory endpoints of these clinical trials, some patients have also been observed to improve subjective mood, reduce anxiety, and improve overall quality of life after using fezonem. Especially in some open-label observational studies, some researchers have noted that the drug may improve sleep disorders through indirect mechanisms, and improving sleep is often one of the key factors in alleviating menopausal mood symptoms. Since mood problems are often closely related to repeated awakenings caused by nocturnal hot flashes, the effects of fizonetant on thermal regulation may further indirectly stabilize mood states by improving sleep continuity.

However, it should be clearly stated that there are currently no sufficient high-quality randomized controlled trials to systematically evaluate the anxiolytic or antidepressant effects of fezonastat using mood swings as the primary endpoint. Therefore, there is no clear evidence to support whether the drug can directly affect the mood regulation center. Its therapeutic mechanism mainly focuses on the regulation of the hypothalamic KNDy neuron system, rather than directly acting on the limbic system or dopamine and serotonin neural pathways involved in emotional control. This means that its "improving mood" performance is mostly a secondary benefit after the relief of hot flashes, rather than the primary mental regulation effect.

Nonetheless, there is potential for future research. Scientists are increasingly paying attention to the cross-regulatory role of the neurokinin system in a variety of physiological functions, including appetite, sleep, pain, and mood. Emerging research in neuroimaging and neurotransmitter metabolism shows that NK3 receptor activity is associated with mood disorders in some animal models. This provides a theoretical basis for the emotion-regulating potential of filzonitant, but there is currently no direct evidence chain in humans. Therefore, some scientific research teams are designing prospective trials with"menopausal mood disorders" as the primary endpoint, trying to explore whether filazonatan can be used as a non-hormonal auxiliary mood intervention option.

In clinical practice, filazonatant is not currently a substitute for antidepressants or medications for anxiety disorders if patients complain of emotional distress. However, if the patient's mood swings are closely related to sleep disruption and hot flashes, and he or she wants to avoid the potential risks of hormone replacement therapy, filazonatant can be a reasonable choice, which may not only relieve vasomotor symptoms but also bring about a certain mood improvement effect.

Reference materials:https://www.veozah.com/